What do you do for patients with HR+ inflammatory breast cancer who do not achieve a pCR with neoadjuvant chemotherapy?
Do you offer additional adjuvant chemotherapy, proceed to adjuvant endocrine therapy, or search for a suitable clinical trial?
Answer from: Medical Oncologist at Academic Institution
I assume the patient in this question is HER2 negative. Inflammatory breast cancer is rarely HR+, HER2-, but for HR+ HER2- invasive breast cancer who do not achieve pCR with neoadjuvant chemotherapy, I would recommend to maximize the benefit of adjuvant hormone therapy.The patient certainly could jo...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I concur - my only suggestion would be the addition of a bone-protecting agent such as zoledronic acid to her adjuvant regimen, since bone is a common site of first recurrence in the ER+/HER2- subtype, even though inflammatory cancers are more likely to recur at visceral sites than non-inflammatory ...